PLERIXAFOR

Details

Stereochemistry	ACHIRAL
Molecular Formula	C28H54N8
Molecular Weight	502.782
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C(N1CCCNCCNCCCNCC1)C2=CC=C(CN3CCCNCCNCCCNCC3)C=C2

InChI

InChIKey=YIQPUIGJQJDJOS-UHFFFAOYSA-N

InChI=1S/C28H54N8/c1-9-29-15-17-31-13-3-21-35(23-19-33-11-1)25-27-5-7-28(8-6-27)26-36-22-4-14-32-18-16-30-10-2-12-34-20-24-36/h5-8,29-34H,1-4,9-26H2

HIDE SMILES / InChI

Molecular Formula	C28H54N8
Molecular Weight	502.782
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022311s016lbl.pdf | https://www.ncbi.nlm.nih.gov/pubmed/19161986

Plerixafor is a bicyclam molecule, which has been identified as a specific antagonist of CXCR4. It had originally been developed as an inhibitor of T-tropic human immunodeficiency virus, but later demonstrated to be an effective mobilizer of hematopoietic stem cells. Plerixafor was approved by FDA for autologous transplantation (in combination with granulocyte-colony stimulating factor) in patients with non-Hodgkin's lymphoma and multiple myeloma under the name Mozobil.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
C-X-C chemokine receptor type 4 5 Target ID: P61073 Gene ID: 7852.0 Gene Symbol: CXCR4 Target Organism: Homo sapiens (Human) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022311s016lbl.pdf	Antagonist 2778		44.0 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Non-Hodgkin's lymphoma 79 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022311s016lbl.pdf	Primary		Approved 8429	MOZOBIL Approved Use Mozobil (plerixafor) injection is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM). Launch Date 2008
Multiple myeloma 159 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022311s016lbl.pdf	Primary		Approved 8429	MOZOBIL Approved Use Mozobil (plerixafor) injection is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM). Launch Date 2008

C_max

Value	Dose	Co-administered	Analyte	Population
1029 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/19135941	240 μg/kg bw single, subcutaneous dose: 240 μg/kg bw route of administration: Subcutaneous experiment type: SINGLE co-administered:		PLERIXAFOR plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
5260 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/19135941	240 μg/kg bw single, subcutaneous dose: 240 μg/kg bw route of administration: Subcutaneous experiment type: SINGLE co-administered:		PLERIXAFOR plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
5.6 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/19135941	240 μg/kg bw single, subcutaneous dose: 240 μg/kg bw route of administration: Subcutaneous experiment type: SINGLE co-administered:		PLERIXAFOR plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
160 ug/kg/h multiple, intravenous Highest studied dose Dose: 160 ug/kg/h Route: intravenous Route: multiple Dose: 160 ug/kg/h Sources: https://pubmed.ncbi.nlm.nih.gov/15385732	unhealthy, 40.2 years n = 3 Health Status: unhealthy Condition: HIV-1 Infection Age Group: 40.2 years Sex: M+F Population Size: 3 Sources: https://pubmed.ncbi.nlm.nih.gov/15385732	Disc. AE: Premature ventricular contractions... AEs leading to discontinuation/dose reduction: Premature ventricular contractions (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/15385732
20 ug/kg/h multiple, intravenous Dose: 20 ug/kg/h Route: intravenous Route: multiple Dose: 20 ug/kg/h Sources: https://pubmed.ncbi.nlm.nih.gov/15385732	unhealthy, 40.2 years n = 8 Health Status: unhealthy Condition: HIV-1 Infection Age Group: 40.2 years Sex: M+F Population Size: 8 Sources: https://pubmed.ncbi.nlm.nih.gov/15385732	Disc. AE: Hepatic enzyme increased, Orthostatic hypotension... AEs leading to discontinuation/dose reduction: Hepatic enzyme increased (1 patient) Orthostatic hypotension (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/15385732
40 ug/kg/h multiple, intravenous Dose: 40 ug/kg/h Route: intravenous Route: multiple Dose: 40 ug/kg/h Sources: https://pubmed.ncbi.nlm.nih.gov/15385732	unhealthy, 40.2 years n = 8 Health Status: unhealthy Condition: HIV-1 Infection Age Group: 40.2 years Sex: M+F Population Size: 8 Sources: https://pubmed.ncbi.nlm.nih.gov/15385732	Disc. AE: Ventricular ectopics... AEs leading to discontinuation/dose reduction: Ventricular ectopics (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/15385732
5 ug/kg/h multiple, intravenous Dose: 5 ug/kg/h Route: intravenous Route: multiple Dose: 5 ug/kg/h Sources: https://pubmed.ncbi.nlm.nih.gov/15385732	unhealthy, 40.2 years n = 7 Health Status: unhealthy Condition: HIV-1 Infection Age Group: 40.2 years Sex: M+F Population Size: 7 Sources: https://pubmed.ncbi.nlm.nih.gov/15385732	Disc. AE: Thrombocytopenia... AEs leading to discontinuation/dose reduction: Thrombocytopenia (serious, 1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/15385732
80 ug/kg/h multiple, intravenous Dose: 80 ug/kg/h Route: intravenous Route: multiple Dose: 80 ug/kg/h Sources: https://pubmed.ncbi.nlm.nih.gov/15385732	unhealthy, 40.2 years n = 5 Health Status: unhealthy Condition: HIV-1 Infection Age Group: 40.2 years Sex: M+F Population Size: 5 Sources: https://pubmed.ncbi.nlm.nih.gov/15385732	Disc. AE: Paresthesia... AEs leading to discontinuation/dose reduction: Paresthesia (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/15385732
160 ug/kg single, oral Dose: 160 ug/kg Route: oral Route: single Dose: 160 ug/kg Sources: https://pubmed.ncbi.nlm.nih.gov/10817726	healthy, >18 years n = 3 Health Status: healthy Age Group: >18 years Sex: M+F Population Size: 3 Sources: https://pubmed.ncbi.nlm.nih.gov/10817726	Sources: https://pubmed.ncbi.nlm.nih.gov/10817726
80 ug/kg single, intravenous Dose: 80 ug/kg Route: intravenous Route: single Dose: 80 ug/kg Sources: https://pubmed.ncbi.nlm.nih.gov/10817726	healthy, >18 years n = 12 Health Status: healthy Age Group: >18 years Sex: M+F Population Size: 12 Sources: https://pubmed.ncbi.nlm.nih.gov/10817726	Other AEs: Diaphoresis... Other AEs: Diaphoresis (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/10817726
320 ug/kg single, subcutaneous Highest studied dose Dose: 320 ug/kg Route: subcutaneous Route: single Dose: 320 ug/kg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022311s000_MedR.pdf Page: p. 83	healthy, adult n = 10 Health Status: healthy Age Group: adult Population Size: 10 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022311s000_MedR.pdf Page: p. 83	Other AEs: Injection site erythema, Paresthesia... Other AEs: Injection site erythema Paresthesia Chest discomfort Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022311s000_MedR.pdf Page: p. 83
0.24 mg/kg 1 times / day multiple, subcutaneous Recommended Dose: 0.24 mg/kg, 1 times / day Route: subcutaneous Route: multiple Dose: 0.24 mg/kg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022311s000_MedR.pdf Page: p.97	unhealthy, adult n = 72 Health Status: unhealthy Age Group: adult Population Size: 72 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022311s000_MedR.pdf Page: p.97	Disc. AE: Anxiety, Arrhythmia... AEs leading to discontinuation/dose reduction: Anxiety (1 patient) Arrhythmia (1 patient) Erythema (1 patient) Decreased appetite (1 patient) Eructation (1 patient) Liver function test abnormal (1 patient) Nausea (2 patients) Vomiting (2 patients) Postural hypotension (1 patient) Sinus tachycardia (1 patient) Staphylococcal bacteremia (1 patient) Insomnia (1 patient) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022311s000_MedR.pdf Page: p.97

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
	inhibitor 1767 inducer 389	inhibitor 1852 inducer 97	inhibitor 1612

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1524 CYP2A6 707 CYP2B6 810 CYP2C8 911 CYP2C19 1478 CYP3A4/5 278 P-gp 1461 CYP2E1 882 CYP4A9/11 37	CYP 270 P-gp 1537	CYP1A2 701 CYP2B6 547 CYP3A4/5 124 P-gp 257 CYP2C19 293

Drug as perpetrator

Target	Modality	Activity
P-gp 1650	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022311s000_ClinPharmR.pdf Page: 60, 104	inconclusive
P-gp 1650	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022311s000_ClinPharmR.pdf Page: 58, 104	inconclusive
CYP1A2 1692	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022311s000_PharmR.pdf Page: 9, 42, 80	no [IC50 >100 uM]
CYP2C19 1553	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022311s000_PharmR.pdf Page: 9, 42, 80	no [IC50 >100 uM]
CYP2C9 1819	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022311s000_PharmR.pdf Page: 9, 42, 80	no [IC50 >100 uM]
CYP2D6 1891	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022311s000_PharmR.pdf Page: 9, 42, 80	no [IC50 >100 uM]
CYP2E1 970	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022291s000_PharmR_P1.pdf Page: 55.0	no [IC50 >100 uM]
CYP3A4/5 335	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022311s000_PharmR.pdf Page: 9, 42, 80	no [IC50 >100 uM]
CYP4A9/11 37	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022291s000_PharmR_P1.pdf Page: 55.0	no [IC50 >100 uM]
CYP1A2 1692	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022311s000_PharmR.pdf Page: 80.0	no
CYP2A6 739	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022311s022lbl.pdf Page: 11.0	no
CYP2B6 1001	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022311s000_ClinPharmR.pdf Page: 59.0	no
CYP2B6 1001	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022311s022lbl.pdf Page: 11.0	no
CYP2C19 1553	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022311s000_PharmR.pdf Page: 80.0	no
CYP2C8 965	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022311s022lbl.pdf Page: 11.0	no
CYP2C9 1819	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022311s000_PharmR.pdf Page: 80.0	no
CYP2D6 1891	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022311s000_PharmR.pdf Page: 80.0	no
CYP3A4/5 335	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022311s000_PharmR.pdf Page: 80.0	no

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
P-gp 1537	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022311s000_ClinPharmR.pdf Page: 58, 104	inconclusive
CYP 270	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022311s000_ClinPharmR.pdf Page: 15, 102	no

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1647	inhibitor 1626 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022311s000_PharmR.pdf Page: 17, 34, 40

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:125354	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:125354
ChemicalBook	CB11011749	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB11011749
MolPort	MolPort-009-019-417	https://www.molport.com/shop/molecule-link/MolPort-009-019-417
Selleck Chemicals	plerixafor	http://www.selleckchem.com/products/plerixafor.html
ZINC	ZINC000022443609	http://zinc15.docking.org/substances/ZINC000022443609
eMolecules	6842643	https://www.emolecules.com/cgi-bin/more?vid=6842643

PubMed

Title	Date	PubMed
Microenvironmental considerations in the application of human mesenchymal stem cells in regenerative therapies.	2008 Dec	19707450
A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma.	2008 Nov	18940680
A novel CXCR4 antagonist for hematopoietic stem cell mobilization.	2008 Nov	18922110
Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cells.	2008 Nov	18847313
Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation.	2008 Sep	18721768
Targeted antagonism of CXCR4 mobilizes progenitor cells under investigation for cardiovascular disease.	2009	19929465
A combination of granulocyte-colony-stimulating factor (G-CSF) and plerixafor mobilizes more primitive peripheral blood progenitor cells than G-CSF alone: results of a European phase II study.	2009	19929463
CXCR4 and mobilization of hematopoietic precursors.	2009	19446720
Plerixafor: in patients with non-Hodgkin's lymphoma or multiple myeloma.	2009	19275275
CXCR4 chemokine receptor antagonists: perspectives in SCLC.	2009 Apr	19335276
Bis-14-membered ring diketal diamines: synthesis and evaluation of their anti-HIV and anti-tumoral activities.	2009 Aug	19356827
Tumor biology and cancer therapy - an evolving relationship.	2009 Aug 13	19678929
BIO5192, a small molecule inhibitor of VLA-4, mobilizes hematopoietic stem and progenitor cells.	2009 Aug 13	19571319
Successful stem cell remobilization using plerixafor (mozobil) plus granulocyte colony-stimulating factor in patients with non-hodgkin lymphoma: results from the plerixafor NHL phase 3 study rescue protocol.	2009 Dec	19896082
Plerixafor.	2009 Feb	19180104
Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient.	2009 Feb	19167685
Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma.	2009 Jan	19135941
CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers.	2009 Jan	18987663
Plerixafor approved for autologous hematopoietic stem-cell transplantation.	2009 Jan 15	19139470
Plerixafor hydrochloride: a novel agent for the mobilization of peripheral blood stem cells.	2009 Jul	19834627
Rescue from failed growth factor and/or chemotherapy HSC mobilization with G-CSF and plerixafor (AMD3100): an institutional experience.	2009 Jun	19182831
Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma.	2009 Jun 4	19363221
AMD3100 is a CXCR7 ligand with allosteric agonist properties.	2009 May	19255243
Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting.	2009 May 7	19228923
[Stem cell harvesting after plerixafor treatment].	2009 Nov 16	19925734
[Mobilisation of haematopoietic stem cells with plerixafor--secondary publication].	2009 Nov 2	19887056
Plerixafor inhibits chemotaxis toward SDF-1 and CXCR4-mediated stroma contact in a dose-dependent manner resulting in increased susceptibility of BCR-ABL+ cell to Imatinib and Nilotinib.	2009 Oct	19657955
International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100).	2009 Oct	19554029
Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma.	2009 Oct 1	19720922
Advances in mobilization for the optimization of autologous stem cell transplantation.	2009 Sep	19603345
Plerixafor (AMD3100) and granulocyte colony-stimulating factor (G-CSF) mobilize different CD34+ cell populations based on global gene and microRNA expression signatures.	2009 Sep 17	19602709
CXCR4 in clinical hematology.	2010	20397073
Anticancer Role of PPARgamma Agonists in Hematological Malignancies Found in the Vasculature, Marrow, and Eyes.	2010	20204067
Molecular Medicine - CHI's 17th International Tri-Conference: Mastering Medicinal Chemistry - CHI's Seventh Annual Conference.	2010 Apr	20373246
Binding of multivalent anionic porphyrins to V3 loop fragments of an HIV-1 envelope and their antiviral activity.	2010 Apr 1	20112333
Plerixafor (Mozobil).	2010 Apr 5	20360661
Plerixafor and pegylated filgrastim: a case of safe and effective hematopoietic stem cell mobilization.	2010 Aug	19966845
Mobilization of peripheral blood stem cells for autologous transplant in non-Hodgkin's lymphoma and multiple myeloma patients by plerixafor and G-CSF and detection of tumor cell mobilization by PCR in multiple myeloma patients.	2010 Feb	19597422
Synthesis and structure-activity relationships of azamacrocyclic C-X-C chemokine receptor 4 antagonists: analogues containing a single azamacrocyclic ring are potent inhibitors of T-cell tropic (X4) HIV-1 replication.	2010 Feb 11	20043638
Plerixafor for stem cell mobilization in patients with non-Hodgkin's lymphoma and multiple myeloma.	2010 Jan	20009003
Peripheral blood stem cell mobilization tactics.	2010 Jan	19996324
A pharmacokinetic study of plerixafor in subjects with varying degrees of renal impairment.	2010 Jan	19748593
Safety and efficacy assessment of plerixafor in patients with multiple myeloma proven or predicted to be poor mobilizers, including assessment of tumor cell mobilization.	2010 Jan	19543330
Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization.	2010 Jan	19483760
A low-molecular-weight entry inhibitor of both CCR5- and CXCR4-tropic strains of human immunodeficiency virus type 1 targets a novel site on gp41.	2010 Jul	20427524
Plerixafor given before the third leukapheresis to rescue an unsuccessful stem cell mobilization with CY and G-CSF.	2010 Jun	19820726
Expression and function of CXCL12/CXCR4 in rat urinary bladder with cyclophosphamide-induced cystitis.	2010 Mar	20032115
Plerixafor: a peripheral blood stem cell mobilizer.	2010 May	20411999
Plerixafor (Mozobil) alone to mobilize hematopoietic stem cells from multiple myeloma patients for autologous transplantation.	2010 May	20067838
Molecular imaging of CXCR4 receptor expression in human cancer xenografts with [64Cu]AMD3100 positron emission tomography.	2010 May 15	20460522

Patents

Sample Use Guides

In Vivo Use Guide

Begin treatment with plerixafor (Mozobil) after the patient has received G-CSF once daily for four days. The recommended dose of plerixafor by subcutaneous injection is based on body weight: 20 mg fixed dose or 0.24 mg/kg of body weight for patients weighing ≤83 kg; 0.24 mg/kg of body weight for patients weighing >83 kg. Administer by subcutaneous injection approximately 11 hours prior to initiation of apheresis.

Route of Administration: Other

In Vitro Use Guide

Human colorectal cancer cell line SW480 was treated with plerixafor at different final concentrations (10, 100, 1000 ng/ml) for 2h. Then, CXCL12 was added daily at 20 ng/mL. MTT assays were performed after 24, 48 and 72 h of plerixafor treatment. Cell viability was significantly suppressed by the drug in a dose-dependent manner. The drug (100 and 1000 ng/mL) significantly inhibited the invasion ability of SW480 cells.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:15:52 GMT 2023` Edited by `admin` on `Fri Dec 15 16:15:52 GMT 2023`
Record UNII	S915P5499N
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PLERIXAFOR

Official Name

English

PLERIXAFOR [ORANGE BOOK]

Common Name

English

PLERIXAFOR [JAN]

Common Name

English

PLERIXAFOR [EMA EPAR]

Common Name

English

Plerixafor [WHO-DD]

Common Name

English

PLERIXAFOR [USAN]

Common Name

English

PLERIXAFOR [MART.]

Common Name

English

plerixafor [INN]

Common Name

English

PLERIXAFOR [VANDF]

Common Name

English

PLERIXAFOR [MI]

Common Name

English

1,1'-(1,4-PHENYLENEBIS(METHYLENE))BIS-1,4,8,11-TETRAAZACYCLOTETRADECANE

Systematic Name

English

1,4,8,11-TETRAAZACYCLOTETRADECANE, 1,1'-(1,4-PHENYLENEBIS(METHYLENE))BIS-

Systematic Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

167903